Literature DB >> 9049977

Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells.

A H Baker1, G W Wilkinson, R M Hembry, G Murphy, A C Newby.   

Abstract

Remodelling of the extracellular matrix resulting from increased secretion of metalloproteinase enzymes (MMPs) is implicated in many pathological conditions, including rheumatoid arthritis, restenosis following balloon angioplasty, atherosclerosis and cancer cell invasion and metastasis. Clear definition of the normal and pathological function of individual MMPs will benefit from approaches that use gene transfer to produce increases in MMP levels that mimic those observed in pathological conditions. Similarly, gene transfer methods leading to controlled increases in levels of the tissue inhibitor of metalloproteinases (TIMPs) will help to define the function of MMPs both in vitro and in vivo. Gene transfer of TIMPs may also have therapeutic potential in pathological conditions where inhibition of MMP activity may be beneficial. We have used the adenovirus serotype 5 vector system to generate replication-deficient recombinant adenoviruses capable of expressing the MMP-9, TIMP-1 or -2 genes. High level expression is driven by the cytomegalovirus major immediate early promoter (CMV IEP). Efficient and selective over-production of each recombinant protein was shown by immunofluorescence in either rabbit smooth muscle cells (SMC) or human MCF-7 adenocarcinoma cells. High level secretion directly dependent on the multiplicity of infection (MOI) was observed for each functional transgene by gelatin zymography. Using a quantitative ELISA assay, levels of recombinant TIMP-1 were detected when SMC were infected with as low as three plaque forming units (pfu) of virus per cell in vitro. A linear increase in TIMP-1 secretion was observed up to 1000 pfu/cell of virus (0.75 ng/10(4) cells/24 h at 3 pfu/cell to 1243 ng/10(4) cells/24h at 1000 pfu/cell). Similar levels of secretion of MMP-9 and TIMP-2 were observed by Western blot analysis using the same MOI of adenovirus. Thus, recombinant adenoviruses are an efficient and flexible system for high level expression of MMPs and TIMPs and will be useful tools in the study of matrix remodelling in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9049977     DOI: 10.1016/s0945-053x(96)90158-4

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  9 in total

1.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling.

Authors:  Ravi Ramani; Kathleen Nilles; Gregory Gibson; Benjamin Burkhead; Michael Mathier; Dennis McNamara; Charles F McTiernan
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.

Authors:  Sherry W Yang; James J Cody; Angel A Rivera; Reinhard Waehler; Minghui Wang; Kristopher J Kimball; Ronald A Alvarez; Gene P Siegal; Joanne T Douglas; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

4.  Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.

Authors:  Stephane Heymans; Florea Lupu; Sven Terclavers; Bjorn Vanwetswinkel; Jean-Marc Herbert; Andrew Baker; Desire Collen; Peter Carmeliet; Lieve Moons
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

5.  Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo.

Authors:  Myung-hee Kim; Thomas M Bodenstine; Lucretia A Sumerel; Angel A Rivera; Andrew H Baker; Joanne T Douglas
Journal:  Cancer Biol Ther       Date:  2006-12-07       Impact factor: 4.742

6.  Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.

Authors:  L R McNally; E L Rosenthal; W Zhang; D J Buchsbaum
Journal:  Cancer Gene Ther       Date:  2008-10-10       Impact factor: 5.987

7.  Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia.

Authors:  Andrew H Baker; Vincenzo Sica; Lorraine M Work; Sharon Williams-Ignarro; Filomena de Nigris; Lilach O Lerman; Amelia Casamassimi; Alessandro Lanza; Concetta Schiano; Monica Rienzo; Louis J Ignarro; Claudio Napoli
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

8.  Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.

Authors:  Sherry W Yang; Diptiman Chanda; James J Cody; Angel A Rivera; Reinhard Waehler; Gene P Siegal; Joanne T Douglas; Selvarangan Ponnazhagan
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

9.  Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.

Authors:  A H Baker; S J George; A B Zaltsman; G Murphy; A C Newby
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.